Show simple item record

dc.contributor.authorvan Rhee, F
dc.contributor.authorRothman, M
dc.contributor.authorHo, K
dc.contributor.authorFleming, S
dc.contributor.authorWong, R
dc.contributor.authorFosså, A
dc.contributor.authorDispenzieri, A
dc.contributor.authorCavet, James
dc.contributor.authorMunshi, N
dc.contributor.authorVermeulen, J
dc.contributor.authorCasper, C
dc.date.accessioned2015-05-19T13:59:33Zen
dc.date.available2015-05-19T13:59:33Zen
dc.date.issued2015en
dc.identifier.citationPatient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab. 2015, 8 (2):207-16 Patienten
dc.identifier.issn1178-1653en
dc.identifier.pmid25736164en
dc.identifier.doi10.1007/s40271-015-0120-5en
dc.identifier.urihttp://hdl.handle.net/10541/554158en
dc.description.abstractMulticentric Castleman's disease (MCD) is a rare lymphoproliferative disorder driven by dysregulated interleukin-6 production. MCD has a poor prognosis, and treatment is generally noncurative and aimed at symptom relief. Siltuximab is a novel, monoclonal interleukin-6 antibody recently shown to be effective in a registration clinical trial. MCD symptoms, such as fatigue, pain, and weakness, are most appropriately quantified using patient-reported outcome (PRO) measures. We assessed the effect of siltuximab on patient perception of symptoms, functional status, and wellbeing using PRO instruments.
dc.language.isoenen
dc.rightsArchived with thanks to The patienten
dc.titlePatient-reported outcomes for multicentric Castleman's disease in a randomized, placebo-controlled study of Siltuximab.en
dc.typeArticleen
dc.contributor.departmentMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USAen
dc.identifier.journalThe Patienten
html.description.abstractMulticentric Castleman's disease (MCD) is a rare lymphoproliferative disorder driven by dysregulated interleukin-6 production. MCD has a poor prognosis, and treatment is generally noncurative and aimed at symptom relief. Siltuximab is a novel, monoclonal interleukin-6 antibody recently shown to be effective in a registration clinical trial. MCD symptoms, such as fatigue, pain, and weakness, are most appropriately quantified using patient-reported outcome (PRO) measures. We assessed the effect of siltuximab on patient perception of symptoms, functional status, and wellbeing using PRO instruments.


This item appears in the following Collection(s)

Show simple item record